Cellular Immunogenicity Assessments in CAR-T Cell Therapies: Current Insights and Future Directions

Area of Science:

• Immunology
• Cellular Therapy
• Biotechnology

Background:

• CAR-T cell therapies can elicit immune responses against the chimeric antigen receptor (CAR) construct and product residuals.
• Assessing both humoral and cellular immunogenicity is recommended by health authorities for CAR-T products.
• While humoral response assays leverage existing anti-drug antibody (ADA) methodologies, cellular immunogenicity assessment presents unique challenges.

Purpose of the Study:

• To provide an overview of strategies for investigating cellular immunogenicity in CAR-T products.
• To detail risk assessment processes, sample handling, and peptide design for eliciting memory responses.
• To share experiences and challenges from ongoing CAR-T cell therapy development.

Main Methods:

• Risk assessment for cellular immunogenicity.
• Guidance on sample collection, processing, and handling.
• Design of CAR domain-related peptides for memory response assessment.

Main Results:

• Discussion of challenges in cellular immunogenicity assays, including cell survival and assay variability.
• Presentation of practical recommendations based on experience with current CAR-T therapies.
• Exploration of the clinical relevance of cellular immunogenicity assessment.

Conclusions:

• A strategic approach is necessary for robust cellular immunogenicity assessment in CAR-T product development.
• Addressing challenges in assay design and execution is key to reliable evaluation.
• Understanding cellular immunogenicity is vital for ensuring the safety and efficacy of CAR-T therapies.